1 research outputs found
Hydroxytyrosol Supplementation Modifies Plasma Levels of Tissue Inhibitor of Metallopeptidase 1 in Women with Breast Cancer
The etiology of breast cancer can be very different. Most antineoplastic drugs are not
selective against tumor cells and also affect normal cells, leading to a wide variety of adverse
reactions such as the production of free radicals by altering the redox state of the organisms.
Therefore, the objective of this study was to elucidate if hydroxytyrosol (HT) (an antioxidant present
in extra virgin olive oil) has a chemomodulatory effect when combined with the chemotherapeutic
drugs epirubicin and cyclophosphamide followed by taxanes in breast cancer patients. Changes in
plasma levels of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of metalloproteinases 1
(TIMP-1) throughout the chemotherapy treatment were studied. Both molecules are involved in cell
proliferation, apoptosis, neoangiogenesis, and metastasis in breast cancer patients. Women with
breast cancer were divided into two groups: a group of patients receiving a dietary supplement of
HT and a control group of patients receiving placebo. The results showed that the plasma levels of
TIMP-1 in the group of patients receiving HT were significantly lower than those levels found in
the control group after the epirubicin-cyclophosphamide chemotherapy.This research was funded by Junta de AndalucÃa, Spain, Servicio Andaluz de Salud: Subvenciones para
la financiacion de la Investigación, Desarrollo, e Innovación Biomédica en Ciencias de la Salud en Biomedicina,
Grant number PI-0695-2012